Charles River Laboratorie (CRL) Misses Q2 EPS by 1c; Extends Agreement with AstraZeneca (AZN)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Charles River Laboratories and AstraZeneca Renew Strategic Partnership Agreement
July 30, 2015 7:01 AM EDT- Leading Global CRO and Global Biopharmaceutical Company Extend Relationship to Accelerate Drug Development -
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has extended its initial three-year partnership with AstraZeneca (NYSE: AZN) for an additional five-year period. Under the agreement, which extends into 2020, Charles River retains its position as AstraZenecas preferred strategic partner for outsourced regulated safety assessment and development DMPK (drug metabolism and pharmacokinetics).
James C. Foster, Chairman,... More
Charles River Laboratories Announces Second-Quarter 2015 Results from Continuing Operations
July 30, 2015 7:00 AM EDTSecond-Quarter Revenue of $339.6 Million
Second-Quarter GAAP Earnings per Share of $1.02
and
Non-GAAP Earnings per Share of $0.96
Updates 2015 Guidance for Celsis Acquisition
Renews Strategic Partnership with AstraZeneca
Plans to Reopen Shrewsbury, Massachusetts Facility in Early 2016
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the second quarter of 2015. For the quarter, revenue from continuing operations was $339.6 million, a decrease of 0.5% from $341.2 million in the second quarter of 2014. Foreign currency... More
